טוען...
MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide – Metabolic Changes are Associated with Enhanced Survival
Current standard of care for glioblastoma (GBM) is surgical resection, radiation, and treatment with Temozolomide (TMZ). However, resistance to current therapies and recurrence are common. To improve survival, agents that target the phosphoinositide-3-kinase (PI3K) signaling pathway, which is activa...
שמור ב:
| הוצא לאור ב: | Mol Cancer Ther |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4873419/ https://ncbi.nlm.nih.gov/pubmed/26883274 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-15-0769 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|